IOL Myopia, Hyperopia Studies Should Include 3-Year Follow Up - FDA Panel
This article was originally published in The Gray Sheet
Executive Summary
Intraocular lens manufacturers pursuing approval for myopia and hyperopia indications should conduct 550-patient studies with three-year follow up, FDA's Ophthalmic Devices Advisory Panel concluded at an Oct. 23 meeting in Silver Spring, Maryland.